Most of what goes wrong with botox migraine treatment cycles goes wrong in the consultation, twelve weeks before anyone is disappointed. An injector who came up through aesthetics is trained by experience to promise a result in two weeks and deliver it. Carry that habit into a headache patient and you will lose roughly one in five of the people this treatment would eventually have helped, because they will quit after cycle one having been told, implicitly, that cycle one was the test.
It is not the test. A non-response is not a non-responder, and the difference between those two phrases is a real number you can quote.
The number
In the pooled double-blind and open-label data from the PREEMPT clinical program, 688 patients received onabotulinumtoxinA. Of those, 49.3% achieved a ≥50% reduction in headache-day frequency during treatment cycle 1. A further 11.3% first responded during cycle 2, and another 10.3% first responded during cycle 3 (Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015;86(9):996–1001).
The same pattern holds across every endpoint the authors examined. First-time responders by cycle 1, 2 and 3 were:
| Endpoint | Cycle 1 | Cycle 2 | Cycle 3 |
|---|---|---|---|
| ≥50% fewer headache days | 49.3% | 11.3% | 10.3% |
| ≥50% fewer moderate/severe headache days | 53.1% | 13.1% | 8.6% |
| ≥50% fewer cumulative headache hours | 54.2% | 11.6% | 7.4% |
| ≥5-point HIT-6 improvement | 56.3% | 14.5% | 7.7% |
Add the columns. Depending on the endpoint, somewhere between 20% and 22% of all eventual responders did not declare themselves until the second or third treatment. The authors' conclusion is the sentence to have in your head: a meaningful proportion of patients who did not respond to the first cycle responded in the second and third.
Stopping at cycle one does not identify non-responders. It manufactures them.
Why this happens, mechanistically
This is not a pharmacokinetic quirk and it is not the patient being difficult. It follows directly from what the drug is doing.
In an aesthetic treatment you are blocking acetylcholine release at a motor endplate. One muscle, one junction, one predictable outcome, visible in a fortnight. We can stop muscle movement predictably with one treatment.
Migraine is a different problem. There is a whole cascade of inflammatory and excitatory neurotransmitters running — glutamate, substance P, CGRP and others — and a sensitisation process that has been building for months or years. Damping that cascade is not the same kind of act as paralysing a muscle. To quiet the noise, you generally need repetitive treatment, and the proportion of responders climbs with each subsequent cycle.
There is a second reason embedded in the pharmacology. Because SNARE-dependent processes include not only vesicle release but also the insertion of pain-transducing receptors into the nociceptor membrane, part of the effect is a progressive reduction in receptor trafficking — and that downregulation is described as likely enhanced in the already-sensitised neuron (Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review. Headache. 2020;60(7):1259–1272). A mechanism that works by progressively stripping receptors off terminals is a mechanism that should accumulate across cycles rather than max out in one.
So the clinical behaviour and the molecular story agree. Good. Tell the patient both.
What the effect size actually is, so you do not oversell the destination either
Setting the expectation about timing is only half the job. The other half is the magnitude, and this is where a lot of consultations quietly overpromise.
A Cochrane systematic review of 28 trials and 4,190 participants concluded that in chronic migraine, botulinum toxin type A reduces headache days per month by 1.9 days versus placebo (95% CI −2.7 to −1.0, high-quality evidence), and migraine days by about 2 days (Herd CP, Tomlinson CL, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6:CD011616).
In the pooled PREEMPT double-blind phases, mean change from baseline in headache days at week 24 was −8.4 with active treatment versus −6.6 with placebo (Dodick DW, Turkel CC, DeGryse RE, et al. Headache. 2010;50(6):921–936).
Those two figures are not in conflict; they are the same result described from different angles. Patients improve substantially on this treatment, and a large part of that improvement is not attributable to the drug. The drug's own contribution is roughly two headache days a month.
In somebody losing more than fifteen days a month, two days back is a real and defensible outcome. It is not remission, and a patient who heard "this will fix your migraines" will experience a textbook success as a failure. Quote the number.
The consultation, said out loud
Say this before the first injection, not after the first disappointment.
On timing. "A large number of people will not respond to the first treatment. That does not mean you are a non-responder. About half of people who respond do so after the first round, but roughly one in five of everyone who eventually benefits doesn't show it until the second or third. So I am asking you to commit to three treatments over about nine months before we decide whether this works for you."
On magnitude. "What the evidence supports is roughly two fewer headache days a month than you'd get from the placebo effect alone, on top of a substantial improvement that a lot of people get from simply being in a structured treatment programme. In someone with your headache burden, that is worth having. It is not a cure, and I am not going to pretend it is."
On what we will measure. "We're not going to judge this on how you feel in the moment on the day you come in. We're going to judge it on your diary — headache days per month, hours lost, and how much you can function. You'll bring the diary each visit."
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Pain Management & Interventional Therapies courses — live patients, expert faculty, and ongoing mentorship.
On the interval. "Treatments are every twelve weeks, no sooner. If you start to feel it wearing off at ten weeks, that's information for me, not a reason to move the appointment."
That last point matters more than it looks. Injectors who let patients pull treatments forward, or who lower the dose or skip muscles because of an unwanted effect, end up delivering something other than the regimen that was studied — and a published anatomy review notes explicitly that lowering doses, avoiding muscles, or delaying repeat treatments may lead to suboptimal efficacy (Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ. Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm. Headache. 2017;57(5):766–777).
Book three, price three, chart three
Operationally, the expectation only holds if your booking and your pricing hold it.
Book the three-cycle course at the outset, not one appointment with a vague suggestion to return. A patient who leaves with cycle two and cycle three already in the diary behaves completely differently from one who has to re-decide in twelve weeks while feeling no better.
Be explicit about what the trial period costs. Whatever your model — covered or cash-pay — the patient should understand at the first consultation what the full assessment period involves, because "come back and we'll see" followed by a second invoice reads as a bait-and-switch even when it is not.
Chart the baseline before you inject, in a form you can re-read: headache days per 28 days, cumulative hours of headache, and a functional measure. Without it you will be litigating "do you feel better?" against a patient's memory of how bad things were in March, which is a conversation nobody wins.
When a non-response really is a non-response
Persistence has a limit, and it is not infinite patience.
The European Headache Federation consensus states that treatment should be stopped if the patient does not respond to the first two to three treatment cycles (Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018;19(1):91). The same consensus also identifies the happier stopping point: sustained reduction to fewer than ten headache days a month for three months.
So the rule is symmetrical and you should state both ends of it at the start. Three cycles to declare a responder. Three cycles of no movement and we stop, and I will tell you we are stopping rather than quietly continuing to bill you.
And there is a third exit that overrides both. If a patient who was controlled stops being controlled, that is not a dosing conversation. Loss of control in a previously stable headache patient is a change in pattern, which is a recognised red flag for a secondary cause — that patient goes back to their neurologist for further evaluation, imaging or workup before anyone adjusts a dose.
What to do differently on Monday
- Replace "let's try one and see" with a three-cycle commitment, spoken and booked.
- Quote two numbers in every consultation: roughly one in five responders declares late, and the drug's own effect is about two headache days a month.
- Take a written baseline before the first injection, or you will have no way to adjudicate the result.
- Hold the twelve-week interval and hold the full regimen. Do not shave the protocol to avoid a side effect without acknowledging the efficacy cost.
- Set the stopping rule at the beginning, in both directions.
- Treat loss of control in a stable patient as a referral, not a titration.
For the aesthetic-side habit this article is arguing against — the reliable, fast, visible motor result — Empire's piece on dynamic versus static wrinkles is a useful contrast in how differently the two endpoints behave.
Neurotoxin fundamentals and injection technique are taught hands-on in Empire's Cosmetic Neurotoxins Training and Complete Botox Training workshops.
This expectation-setting framework reflects Dr. Chris Croley's clinical practice as taught in Empire Medical Training's hands-on curriculum, together with the published trial data cited above. This article is educational and is not a substitute for training.
Frequently Asked Questions
How many treatments before you decide it is not working?
Three. In the pooled PREEMPT data, 49.3% of patients responded in cycle 1, with a further 11.3% and 10.3% first responding in cycles 2 and 3 — about one in five eventual responders declares late. European consensus guidance recommends stopping if there is no response to the first two to three cycles.
Why does the first cycle work less reliably than a cosmetic treatment?
Because you are not producing the effect the same way. A cosmetic result comes from blocking acetylcholine at a motor endplate, which is immediate and predictable. Migraine prophylaxis comes from damping an ongoing cascade of inflammatory neurotransmitters and progressively reducing pain-receptor trafficking in sensitised nociceptors, which accumulates across cycles.
How much benefit should I tell a patient to expect?
A Cochrane review found about 1.9 fewer headache days and 2 fewer migraine days per month versus placebo in chronic migraine. In the PREEMPT pooled data the absolute improvement was larger, but so was the placebo response. Quote the incremental number, not the total, and say explicitly that this is prevention rather than cure.
Should I increase the dose if cycle one does nothing?
No. The approved regimen is a fixed 155 Units across 31 sites every 12 weeks, and the responder data describing late response were generated on that regimen, not on escalating doses. Hold the protocol and hold the interval. If a previously controlled patient loses control, refer rather than escalate.
Disclaimer
This article reflects the clinical opinions and experience of Dr. Chris Croley, Chief Medical Officer, Empire Medical Training, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.
